Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-01-04

FDA Approved: VENLAFAXINE — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

The FDA approved a supplemental application from BluePoint Laboratories for Venlafaxine (venlafaxine hydrochloride), a generic antidepressant.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Venlafaxine (Venlafaxine)
  • Venlafaxine hydrochloride (Venlafaxine hydrochloride)

Snippet

SUPPL AP for VENLAFAXINE (VENLAFAXINE)